Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Resting-State fMRI in MS: General Concepts and Brief Overview of Its Application.
Analysis of HLA-DQB1*0602 in Multiple Sclerosis Patients in Khuzestan Province, Iran.
How scientists fool themselves - and how they can stop.
A practical approach to the diagnosis and management of sleep disorders in patients with multiple sclerosis.
Vagomimetic effects of fingolimod: physiology and clinical implications.
(P150) assessment of acute and late toxicities of intracranial stereotactic radiosurgery in multiple sclerosis patients.
[Physiotherapy and neurogenic lower urinary tract dysfunction in multiple sclerosis patients: A randomized controlled trial].
Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Upregulation of ciliary neurotrophic factor in astrocytes by aspirin: Implications for remyelination in multiple sclerosis.
Door-to-door survey of major neurological disorders (project) in Al Quseir City, Red Sea Governorate, Egypt.
Neuroimaging evidence of deficient axon myelination in Wolfram syndrome.
The Effects of "Pilates" Based Core Stability Training in Ambulant People With Multiple Sclerosis: A Multi-Centre, Randomised, Assessor-Blinded, Controlled Trial.
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
OGR1/GPR68 Modulates the Severity of Experimental Autoimmune Encephalomyelitis and Regulates Nitric Oxide Production by Macrophages.
Transverse Myelitis.
Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis.
White matter disease: Longest follow-up of rituximab for neuromyelitis optica.
A profile of childhood neuropathies at a university hospital in Oman.
Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study.
Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment.
Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelination.
Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis.
RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis.
Intranasal brain delivery of cationic nanoemulsion-encapsulated TNFα siRNA in prevention of experimental neuroinflammation.

Pages